FDAs 2025 Increase in Warning Letters on Compounded Drug Advertising In recent remarks at the Food and Drug Law Institutes Enforcement, Litigation, and Compliance Conference, the director of the Office of Compliance within FDAs Center for Drug Evaluation and Research's (CDER) noted that 22% of warning letters that CDER issued in fiscal year (FY) 2025 were sent to telehealth platforms and other entities related to claims made regarding compounded drug products, including compounded GLP-1s
These medications work by mimicking the action of the naturally occurring GLP-1 hormone, which stimulates insulin secretion in response to food intake, suppresses glucagon release, slows gastric emptying, and reduces appetite
Work over the last decade has also underscored their complexity
Supported by contemporary medical research and rigorous FDA regulatory evaluation, this formulation represents a true scientific advancement. Why Pryxo Arthritis Gel is Your Best Choice Advanced Transdermal Delivery: Gently and steadily releases active ingredients for up to 8 hours, ensuring continuous relief without gastrointestinal damage